Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015;11(3):421-9.
doi: 10.2217/fon.14.269.

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Filippo de Marinis  1 , Alain Vergnenegre, Antonio Passaro, Catherine Dubos-Arvis, Enric Carcereny, Ana Drozdowskyj, Ali Zeaiter, Pablo Perez-Moreno, Rafael Rosell
Affiliations
Clinical Trial

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Filippo de Marinis et al. Future Oncol. 2015.

Abstract

Aim: This analysis investigates incidence and time course of rash in the EURTAC study.

Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy.

Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment.

Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

Keywords: EGFR; erlotinib; non-small-cell lung cancer; rash; safety.

PubMed Disclaimer

Publication types

MeSH terms